TY - JOUR T1 - Identifying the potential role of insomnia on multimorbidity: A Mendelian randomization phenome-wide association study in UK Biobank JF - medRxiv DO - 10.1101/2022.01.11.22269005 SP - 2022.01.11.22269005 AU - Mark J Gibson AU - Deborah A Lawlor AU - Louise AC Millard Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/14/2022.01.11.22269005.abstract N2 - Objectives To identify the breadth of potential causal effects of insomnia on health outcomes and hence its possible role in multimorbidity.Design Mendelian randomisation (MR) Phenome-wide association study (MR-PheWAS) with two-sample Mendelian randomisation follow-up.Setting Individual data from UK Biobank and summary data from a number of genome-wide association studies.Participants 336,975 unrelated white-British UK Biobank participants.Exposures Standardised genetic risk of insomnia for the MR-PheWAS and genetically predicted insomnia for the two-sample MR follow-up, with insomnia instrumented by a genetic risk score (GRS) created from 129 single-nucleotide polymorphisms (SNPs).Main outcomes measures 11,409 outcomes from UK Biobank extracted and processed by an automated pipeline (PHESANT). Potential causal effects (i.e., those passing a Bonferroni-corrected significance threshold) were followed up with two-sample MR in MR-Base, where possible.Results 437 potential causal effects of insomnia were observed for a number of traits, including anxiety, stress, depression, mania, addiction, pain, body composition, immune, respiratory, endocrine, dental, musculoskeletal, cardiovascular and reproductive traits, as well as socioeconomic and behavioural traits. We were able to undertake two-sample MR for 71 of these 437 and found evidence of causal effects (with directionally concordant effect estimates across all analyses) for 25 of these. These included, for example, risk of anxiety disorders (OR=1.55 [95% confidence interval (CI): 1.30, 1.86] per category increase in insomnia), diseases of the oesophagus/stomach/duodenum (OR=1.32 [95% CI: 1.14, 1.53]) and spondylosis (OR=1.57 [95% CI: 1.22, 2.01]).Conclusion Insomnia potentially causes a wide range of adverse health outcomes and behaviours. This has implications for developing interventions to prevent and treat a number of diseases in order to reduce multimorbidity and associated polypharmacy.What this paper addsWhat is already known on this topicWhat is already known on this topicInsomnia symptoms are widespread in the population and insomnia is the second most common mental health disorder after anxiety disorders.Insomnia might have broad and numerous effects on health and multimorbidity, but both observational and Mendelian randomisation studies have focused on select hypothesised associations/effects rather than taking a systematic hypothesis-free approach across many health outcomes.What this study addsWhat this study addsThis study uses a hypothesis-free approach to systematically identify causal effects of insomnia on 11,409 health outcomes; it identified 437 potential causal effects and for 71 that could be followed-up with two-sample MR, 25 showed evidence of a causal effect and were directionally consistent across all analyses.These findings identify potential routes for developing interventions to prevent and treat a number of diseases and reduce multimorbidity and polypharmacy.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/disclosure-of-interest/. DAL has received support from Roche Diagnostics and Medtronic Ltd for biomarker research unrelated to this paper. MJG and LACM declare no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis work was supported by a Medical Research Council (MRC) PhD studentship to MJG (grant code: MC_UU_00011/7) and the British Heart Foundation (AA/18/7/34219). DAL is further supported by a British Heart Foundation Chair (CH/F/20/90003) and National Institute of Health Research Senior Investigator award (NF-0616-10102). LACM is supported by a University of Bristol Vice-Chancellors fellowship. All three authors work in a Unit that is funded by the University of Bristol and Medical Research Council (MC_UU_00011/1, MC_UU_00011/6 and MC_UU_00011/7). The funders had no role in the study design, collection or analysis of data, or interpretation of results. The views expressed in this paper are those of the authors and not necessarily any funder or acknowledged person/institution.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data collection in UK Biobank was approved by the NHS National Research Ethics Service (ref 11/NW/0382).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available on request from the UK Biobank or 23andMe. The full GWAS summary statistics for the 23andMe discovery data set will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Please visit https://research.23andme.com/collaborate/#dataset-access/ for more information and to apply to access the data. ER -